Kephera Diagnostics operates a CLIA-certified laboratory providing moderate- and high-complexity diagnostic testing for emerging and neglected diseases, including a variety of parasitic diseases.
Deep infectious disease expertise
Our laboratory testing services benefit from Kephera’s expertise in the field of infectious diseases. Testing protocols leverage Kephera’s technological expertise and experience with laboratory-developed tests. Our team of dedicated scientists collaborates with leading public health institutions and medical researchers to continually expand our ability to provide vital testing services.
Responsive service delivery
Working with Kephera Diagnostics is easy and convenient for clinicians. Once you register with Kephera and we receive the sample, we return results in less than 14 days. Learn more about the ordering process.
Kephera currently provides lab testing services for the following infectious diseases.
Kephera offers Lyme disease testing for antibodies to Borrelia burgdorferi with the Modified Two-Tier Testing (MTTT) protocol, and also with the C6 ELISA as a single assay. The MTTT protocol makes use of C6 ELISA followed by VlsE ELISA, run serially as shown in the table below. This combination of assays has been reported in published studies to offer sensitivity and specificity equal to or better than other MTTT and STTT protocols that used a variety of Lyme disease assays1,2. The C6 ELISA has been shown in numerous studies to be both highly sensitive and highly specific for B. burgdorferi sensu lato, including European strains B. afzelii and B. garinii3–6.
Kephera’s neurocysticercosis (NCC) IgG assay is a laboratory-developed test that uses recombinant antigens to detect IgG antibodies to the corresponding native glycoproteins, derived from Taenia solium cysts, that form the basis of the CDC Enzyme Immunotransfer Blot (EITB) assay. The assay is performed in microplate ELISA format.
Kephera’s Clonorchis sinensis (liver fluke) IgG assay is a laboratory-developed test that uses recombinant antigens to detect IgG antibodies to the parasite. The assay is performed in microplate ELISA format.
Kephera uniquely offers two independent assays for detection of IgG antibodies to the parasite Trypanosoma cruzi for the serodiagnosis of Chagas disease. Serum samples are tested in parallel on the Wiener Chagatest ELISA recombinante v.3.0 and the Infynity Multi-Cruzi assays, in line with current testing standards that require concordant results on two independent assays to yield a final result. The Wiener Chagatest is FDA-approved for in vitro diagnosis, while Multi-Cruzi is a recently developed assay offered exclusively in the U.S. by Kephera Diagnostics.
Chagatest ELISA recombinante v.3.0
The Wiener Chagatest ELISA recombinante v.3.0 is an FDA-approved, qualitative assay for detection of anti-Trypanosoma cruzi IgG antibodies. Six recombinant antigens derived from T. cruzi are immobilized in microplate wells. Specific anti-T. cruzi antibodies present in a serum or plasma sample will bind to the immobilized antigens. After washing to remove unbound antibodies, an anti-human IgG-enzyme conjugate is added, followed by an enzyme substrate that will change color if the conjugate has bound to antigen-antibody complexes. Optical density of the resulting color is read using a microplate reader.
Infynity Biomarkers Multi-Cruzi
The Infynity Multi-Cruzi is a multiplex immunoassay for detection of anti-Trypanosoma cruzi IgG antibodies7,8. 15 recombinant T. cruzi antigens are printed in an array in each well of a 96-well microplate. Serum or plasma samples are incubated in the microplate wells and if anti-T. cruzi antibodies are present, they will bind to the array in a specific pattern. After washing away the unbound material, an anti-human IgG-enzyme conjugate is added, which will bind to any antigen/antibody complexes, followed by an enzyme substrate, which converts to an insoluble colored precipitate upon contact with the enzyme conjugate. A specialized microplate array reader is used in combination with an assay-specific algorithm to interpret results.
Pegalajar-Jurado A, Schriefer ME, Welch RJ, Couturier MR, MacKenzie T, Clark RJ, et al. Evaluation of Modified Two-Tiered Testing Algorithms for Lyme Disease Laboratory Diagnosis Using Well-Characterized Serum Samples. J Clin Microbiol [Internet]. 2018 Aug 1 [cited 2018 Aug 30];56(8):e01943-17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29743307
Branda JA, Strle K, Nigrovic LE, Lantos PM, Lepore TJ, Damle NS, et al. Evaluation of modified 2-tiered serodiagnostic testing algorithms for early Lyme disease. Clinical Infectious Diseases. 2017;64(8):1074–80.
Wormser GP, Schriefer M, Aguero-Rosenfeld ME, Levin A, Steere AC, Nadelman RB, et al. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis [Internet]. 2013 Jan [cited 2018 Jun 15];75(1):9–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23062467
Wormser GP, Liveris D, Hanincová K, Brisson D, Ludin S, Stracuzzi VJ, et al. Effect of Borrelia burgdorferi genotype on the sensitivity of C6 and 2-tier testing in North American patients with culture-confirmed Lyme disease. Clin Infect Dis. 2008 Oct;47(7):910–4.
Wormser GP, Nowakowski J, Nadelman RB, Visintainer P, Levin A, Aguero-Rosenfeld ME. Impact of clinical variables on Borrelia burgdorferi-specific antibody seropositivity in acute-phase sera from patients in North America with culture-confirmed early Lyme disease. Clinical and Vaccine Immunology. 2008;15(10):1519–22.
Branda JA, Strle F, Strle K, Sikand N, Ferraro MJ, Steere AC. Performance of United States serologic assays in the diagnosis of lyme borreliosis acquired in Europe. Clinical Infectious Diseases. 2013;
Granjon E, Dichtel-Danjoy ML, Saba E, Sabino E, Campos de Oliveira L, Zrein M. Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease. PLoS Negl Trop Dis. 2016;10(4):e0004596.
Francisco AF, Saade U, Jayawardhana S, Pottel H, Scandale I, Chatelain E, et al. Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure. PLoS Negl Trop Dis [Internet]. 2022 [cited 2023 May 25];16(10). Available from: /pmc/articles/PMC9560623/
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: